Portfolio Building Block World Pharma and Biotech Index ETF (PBPH) is an exchange-traded fund that seeks to track the performance, before fees and expenses, of the BITA Global Pharma and Biotech Select Index, providing passively managed exposure to pure-play companies in the global pharmaceutical and biotechnology industries from developed markets. The fund's primary product is a diversified portfolio of equity securities from pharmaceutical and biotechnology firms with publicly traded ordinary shares listed on major stock exchanges, selected via a rules-based methodology emphasizing companies generating substantial revenue from drug development, manufacturing, and related healthcare innovations; top holdings include leading names such as Eli Lilly and Co., Johnson & Johnson, AbbVie Inc., and AstraZeneca PLC, representing approximately 64% of assets with predominant allocation to the healthcare sector (99.20%). Launched on November 25, 2025, under Tidal Trust IV and managed by Tidal Investments LLC with portfolio managers Charles Ragauss and Qiao Duan, the ETF operates from a United States domicile, trades on Nasdaq, maintains a gross expense ratio of 0.13%, and targets institutional and retail investors seeking targeted sector exposure without active management.
As part of the recently introduced Portfolio Building Block ETF suite, PBPH represents a major strategic launch by Tidal Investments in late 2025, alongside sibling funds like the Portfolio Building Block European Banks Index ETF (PBEU) and Portfolio Building Block Integrated Oil and Gas and Exploration and Production Index ETF (PBOG), all benchmarked to proprietary BITA indices for enhanced portfolio construction tools in healthcare, financials, and energy sectors. The fund commenced trading with initial net assets of approximately $1.00 million and has maintained low trading volume reflective of its nascent stage, with no reported partnerships, acquisitions, funding rounds, or operational reorganizations since inception as of December 2025. Geographically, PBPH focuses on developed markets worldwide, with holdings diversified across U.S. (65.23%) and non-U.S. stocks (33.96%), serving investors building sector-specific allocations in global healthcare without direct exposure to emerging markets or other asset classes.